TY - JOUR T1 - Sudden Onset of Interstitial Lung Disease Induced by Gefitinib in a Lung Cancer Patient with Multiple Drug Allergy JF - Anticancer Research JO - Anticancer Res SP - 415 LP - 418 VL - 25 IS - 1B AU - KEISUKE AOE AU - AKIO HIRAKI AU - TOMOYUKI MURAKAMI AU - TADASHI MAEDA AU - YOSHIKI UMEMORI AU - HIDEKI KATAYAMA AU - RYOSUKE EDA AU - HIROYASU TAKEYAMA Y1 - 2005/01/01 UR - http://ar.iiarjournals.org/content/25/1B/415.abstract N2 - Gefitinib is an oral selective inhibitor of the epidermal growth factor receptor tyrosine kinase which is effective for patients with advanced non-small cell lung cancer. A 75-year-old man with advanced adenocarcinoma of the lung was treated with gefitinib. He had a history of allergy to several antibiotics and Welder's lung. Two days after initiation, he developed acute interstitial lung disease (ILD) and died of respiratory failure due to progression of ILD. Critical assessment pointed to gefitinib as the likely cause of this complication. This is the first report of rapid gefitinib-induced ILD. This case should alert physicians to the potential for dangerous pulmonary side-effects of gefitinib therapy, especially in patients with drug allergy. Copyright© 2005 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved ER -